GrOwnValve Achieves Primary Safety Endpoint in First-in-Human Heart Valve Study

Barchart · 1d ago

All five patients complete six-month follow-up without predefined prosthesis-related safety events

BERLIN, Oct. 26, 2026 /PRNewswire/ -- GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, today announced the achievement of the primary safety endpoint in the initial five-patient cohort of its GECT-DZHK28 first-in-human clinical study at the German Heart Center of Charité (DHZC).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.